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Mucus pathology in cystic fibrosis (CF) has been known for as long as the disease has
been recognized and is sometimes called mucoviscidosis. The disease is marked by
mucus hyperproduction and plugging in many organs, which are usually most fatal in the
airways of CF patients, once the problem of meconium ileus at birth is resolved. After the
CF gene, CFTR, was cloned and its protein product identified as a cAMP-regulated Cl2
channel, causal mechanisms underlying the strong mucus phenotype of the disease
became obscure. Here we focus on mucin genes and polymeric mucin glycoproteins, ex-
amining their regulation and potential relationships to a dysfunctional cystic fibrosis trans-
membrane conductance regulator (CFTR). Detailed examination of CFTR expression in
organs and different cell types indicates that changes in CFTR expression do not always
correlate with the severity of CF disease or mucus accumulation. Thus, the mucus hyperpro-
duction that typifies CF does not appear to be a direct cause of a defective CFTR but, rather,
to be a downstream consequence. In organs like the lung, up-regulation of mucin gene
expression by inflammation results from chronic infection; however, in other instances
and organs, the inflammation may have a non-infectious origin. The mucus plugging phe-
notype of the b-subunit of the epithelial Naþ channel (bENaC)-overexpressing mouse is
proving to be an archetypal example of this kind of inflammation, with a dehydrated
airway surface/concentrated mucus gel apparently providing the inflammatory stimulus.
Data indicate that the luminal HCO3
2 deficiency recently described for CF epithelia may
also provide such a stimulus, perhaps by causing a mal-maturation of mucins as they are
released onto luminal surfaces. In any event, the path between CFTR dysfunction and mucus
hyperproduction has proven tortuous, and its unraveling continues to offer its own twists and
turns, along with fascinating glimpses into biology.
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Mucus has long been recognized to reside onthe moist, external and internal surfaces of
the body. In the early 1930s, for instance, long
before he became famous for the codiscovery of
penicillin, Howard Florey wrote extensively on
mucus secretion in the intestine and airways, as
well as on the functions of mucus (Florey 1930;
Goldsworthy and Florey 1930; Florey et al.
1932)5; his observations strike a surprisingly
contemporary chord! The concept of mucus
as a barrier against harsh environments or path-
ogens, however, is a more recent concept that
was described first for the stomach (Forte and
Forte 1970) and the cervix (Enhorning et al.
1970) in 1970. Since that time, our appreciation
of this barrier function offered by mucus has
been refined and generalized (Cone 2009) and
is presently being appreciated at the molecular
level (Pickles 2004; Linden et al. 2008). Also
more recently appreciated is the role that the
breakdown of the mucus barrier plays in inflam-
matory diseases (Rhodes 1989; Knowles and
Boucher 2002; Johansson et al. 2010). Studies
of the genetic disease cystic fibrosis (CF) have
been central to much of ourcurrent understand-
ing of the function of the mucus barrier in health
and its dysfunction in disease, especially with
respect to chronic infection and inflammation
of the airways in the lungs of CF patients.
Mucus on most epithelial surfaces, such as
airways and ocular surfaces, resides as a single
layer of polymeric mucin gel (Hollingsworth
and Swanson 2004), a few tens of micrometers
thick, overlying the epithelial glycocalyx, which
includes a class of mucins tethered to the apical
plasma membrane (Hattrup and Gendler 2008;
Govindarajan and Gipson 2010). In the stom-
ach and colon, however, there are two layers of
mucus, one that is adherent, forms from mucins
released by goblet cells, and is impermeable to
bacteria. The second is more luminal and non-
adherent, forms from the enzymatic processing
of mucins that are continuously released into
the adherent layer, and harbors bacteria (Allen
et al. 1984; Taylor et al. 2004; Johansson et al.
2011). Under normal conditions, the mucus
barrier on epithelia functions as part of the in-
nate immune system; however, under condi-
tions of inflammation, mucus production is
accelerated as part of the body’s response to
infection or other insults, and the resulting hy-
perproduction can be deleterious to the health
of the patient. This phenomenon of mucus hy-
perproduction and mucus plugging in the air-
ways is especially true for CF patients, as we
consider below.
CYSTIC FIBROSIS, MUCUS, AND MUCINS
Overview
Cystic fibrosis is often referred to as “mucovisci-
dosis” in early descriptions of the disease
(Farber et al. 1943) because copious amounts
of viscid mucus were observed in the gastroin-
testinal and respiratory tracts of children when
the disease was first reported in 1938 (Anderson
1938). Mucus is a viscoelastic material that
covers and protects the apical surfaces of the
respiratory, gastrointestinal, and reproductive
epithelial tracts and is a composite of compo-
nents secreted apically (luminally) by epithelial
and glandular cells in the mucosal epithelium
(Rose 2006). Mucin glycoproteins (mucins)
are major macromolecular components of
lung mucus (Rose et al. 1987; Kesimer et al.
2008). Mucins (MUCs) are heavily O-glycosy-
lated (Fig. 1A,B) and are now identified by the
MUC genes that encode their protein back-
bones. Because these are well described (Rose
and Voynow 2006; Thornton et al. 2007; Hattrup
and Gendler 2008), they are only briefly re-
viewed below. The potential involvement in CF
of polymeric (Fig. 1A) (Rose 1988; Rose and
Voynow 2006) and membrane-tethered mucins
(Fig. 1B) (Hattrup and Gendler 2008) has been
reviewed. We review more recently published
information on mucins and mucin gene regula-
tion and integrate it into our evolving under-
standing of the contribution of mucins to CF
5Many of the manuscripts of Florey and other authors pub-
lishing in the 1800s and early 1900s are now available
through the archives of PubMed Central, part of the Nation-
al Library of Medicine. The archive can be searched through
PubMed (available at http://www.ncbi.nlm.nih.gov/sites/
entrez), but, because the older references in the PMC data-
base may not be included in the main, PubMed database,
one must select the PMC database to access it.
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disease, especially with regard to the localization
and expression of the cystic fibrosis transmem-
brane regulator (CFTR) gene, the causative gene
of CF disease.
The initial pathology in CF is manifested in
mucosal epithelia and represents the basis for
the long-standing concept of a fundamental
mucus abnormality in CF patients (Fig. 1C).
This is supported by ultrasound studies in the
gastrointestinal tract, wherein 90% of CF fetuses
manifest inspissated meconium in their distal
ileum during the 17–19-wk gestation period
(Duchatel et al. 1993). Although this is generally
reabsorbed, a small percentage of CF infants
present with mucin-containing meconium ile-
us at birth (Schachter and Dixon 1965). Inter-
estingly, CFTR-null (Cftr2/2) mice, pigs, and
ferrets, that is, gene-targeted animal models that
that do not express the Cftr gene, have meconi-
um ileus at birth (Snouwaert et al. 1992; Rogers
et al. 2008; Sun et al. 2010; Klymiuk et al. 2011).
This mucus overproduction, which reflects
markedly increased levels of Muc1 mRNA and
a moderate increase of Muc1 mucin, is obviated
in CF mice that do not express the Muc1 gene
(Parmley and Gendler 1998), suggesting that the
membrane-tethered mucin Muc1 plays an im-
portant role in mucus obstruction in the CF
colon.
Inspissated material is also found in the pan-
creas and bile ducts in CF patients and CFanimal
models. Although these tissues are not typically
described as mucosal epithelia, the pancreas ex-
presses MUC6 mRNA and the gallbladder ex-
presses both MUC6 and MUC5B mRNA (Reid
et al. 1997b; Hollingsworth 1999). Inspissated
material in the pancreatic ducts of CF patients
contains MUC6 mucin (Reid et al. 1997b; Hol-
lingsworth 1999), whereas CF mice show higher
Muc6 mRNA and protein levels than wild-type
mice in their pancreatic ducts (Gouyer et al.
2010). These data suggest that the absence of
functional CFTR/Cftr protein may impact reg-




















Figure 1. Mucin domain maps and mucus. (A) Domain map for a generic, polymeric mucin (after Fig. 1a in
Thornton et al. 2007). Indicated are the vWF vB, vC, and D domains, a Cys-rich domain, and the carboxy-
terminal cystine knot (CK), in addition to the central glycosylated TR domains. The map most closely represents
MUC2; unlike MUC2, MUC5AC and MUC5B have multiple Cys-rich domains within the glycosylated repeat
domain (Rose and Voynow 2006). (B) Domain map for a tethered mucin, MUC1 (after Fig. 1A in Hattrup and
Gendler 2008). Indicated are the cytoplasmic tail (CT), transmembrane (TM), and SEA domains, as well as the
glycosylated TR domains, which for MUC1 can have considerable variation in the number of TRs (Hattrup and
Gendler 2008). (C) Mucus harvested from HBE cell cultures, stained with fluorescent wheat germ agglutinin and
concentrated to 2.5% or 6.5% solids, from a control of 1.5%. The highest concentration (6.5% solids) is
representative of CF sputum. (Panel C is from Matsui et al. 2005; reprinted, with express permission, from
the author.)
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the gastrointestinal tract and contribute to the
formation of materials that block pancreatic
acini and ducts in CF. Gallstones are frequent
in CF patients and generally contain “black” pig-
ment (i.e., Ca bilirubinate) with an appreciable
cholesterol admixture. CF mice exhibit similar
pathophysiological changes in their gallbladder
bile (Freudenberg et al. 2010). Whether or not
mucins are part of the gallstone admixture in CF
bile is not yet known, but the biliary tract can
express and secrete mucins in disease conditions
(Gouyer et al. 2010).
In contrast to the gastrointestinal tract, there
are no marked morphological abnormalities in
the airways of CF fetuses or neonates, and mucus
obstruction in CF airways is not observed pre-
natally or at birth (Zuelzer and Newton 1949;
Sturgess and Imrie 1982). Postnatally, dilated
acinar and duct lumens in submucosal glands
are observed in CF airways early in life with the
earliest consistent pathological lesion and evi-
dence of mucus obstruction being observed in
the bronchioles (Sturgess 1982). Nevertheless,
pulmonary complications (reflecting predispo-
sition to infection and recurring cycles of infec-
tion) result in airway mucus obstruction and
progressive lung disease, which are the major
cause of morbidity and mortality in CF patients
(Boat et al. 1989; Welsh et al. 1995). The exis-
tence of mucus plugs containing mucins, bacte-
ria, and neutrophils that block the lower airways
of CF patients and of sputum with similar char-
acteristics continue to support the concept of
“abnormal” lung mucus and/or mucins in CF.
Further exacerbating the problem of stagnant
mucus in CF airways, the airway surface liquid
of CF patients has decreased bactericidal activity
(Smith et al. 1996), which may be due to the
decreased lactoferrin activity observed in CF
sputum (Rogan et al. 2004). In addition, CFTR
transport of glutathione and its thiocyanate con-
jugates is defective in CF airways, inactivating
the oxidative antimicrobial system in CF mucus
(Childers et al. 2007; Moskwa et al. 2007).
Interestingly, genetic knockout of Cftr in
mice does not cause lung disease, although the
gastrointestinal phenotype of CF disease, meco-
nium ileus, is duplicated in the CFTR-null
mouse quite well (Snouwaert et al. 1992). The
lack of CF lung disease in the mouse model re-
flects the dominant expression of a Ca2þ-acti-
vated Cl2 channel and poor expression of CFTR
in the lungs. The mouse model that produces
the best CF-like lung phenotype is the transge-
nic overexpression, selectively in Clara cells, of
bENaC, the b-subunit of the epithelial Naþ
channel (Mall et al. 2004a; Zhou et al. 2011).
The increased liquid absorption in the lungs of
the bENaC Tg mouse appears to drive an in-
flammatory process that results in mucus meta-
plasia and overproduction, and mucus plugging
(Livraghi et al. 2009). We pursue this “non-in-
fectious inflammation” phenomenon below, af-
ter consideration of infectious inflammation.
Mucin Glycoproteins
Mucins are large glycoproteins with a carbohy-
drate content that accounts for 50%–90% of
their molecular mass. They are characterized
by a high number of O-glycans and an extensive
number of tandem repeats (TRs) in their pro-
tein backbones that are high in threonine and/
or serine and proline, as well as domains specific
to individual mucins (Fig. 1A,B). TR domains
are a characteristic feature that distinguishes
mucins from mucin-like glycoproteins, espe-
cially membrane-bound glycoproteins/recep-
tors that have extracellular regions high in
serine, threonine, and proline. Mucins are clas-
sified by their MUC protein backbones, which
are encoded by one of 18 MUC genes, as mem-
brane-tethered (MUC1, MUC3A, MUC3B,
MUC4, MUC11, MUC12, MUC13, MUC16,
MUC17, MUC20), secreted, polymeric, and
cysteine rich (MUC2, MUC5AC, MUC5B,
MUC6, MUC19) or secreted and non-cysteine
rich (MUC7, MUC8, MUC9) mucins (Rose
and Voynow 2006). Models of secreted mucins
and the membrane-tethered MUC1 mucin are
shown in Figure 1 A and B. MUC1 is typically
expressed in the apical membrane of epithelial
cells. Mucins show somewhat restricted tissue
and cell specificity, which is often altered in dis-
ease states, especially cancer. The gel-forming
mucins are synthesized in goblet and mucosal
cells in epithelial tracts (Table 1) and stored in
secretory granules until stimulated for luminal
S.M. Kreda et al.



















release by secretagogues (Kim et al. 2003; Davis
and Dickey 2008).
Mucus and Mucins in Healthy and CF Lungs
Mucus and mucins provide a physiological bar-
rier to environmental toxins and pathogens
(Hollingsworth and Swanson 2004; Linden
et al. 2008; Cone 2009) and are part of the first
line of innate immune responses in the con-
ducting airway epithelium (Knowles and Bou-
cher 2002). Polymeric mucins are the major
macromolecular components of lung mucus
and form viscoelastic gels by interacting with
other mucins and/or proteins (Fig. 1C) (Litt
et al. 1974; Rose et al. 1979, 1987). MUC5AC
and MUC5B are the predominant mucins in
lung secretions. In healthy lungs, MUC5AC
mRNA expression is restricted to goblet cells
in the conducting airway epithelium. MUC5B
mRNA is expressed in mucosal cells of the sub-
mucosal glands, but is also expressed in goblet
cells in the second trimester during gestation
(Reid et al. 1997a) and recently has been ob-
served at the protein level in adult lungs (Fig.
2, left panel). Although altered localization of
cellular expression of secretory mucin genes has
been reported—MUC5B mRNA in goblet cells
in patients with various obstructive lung dis-
eases (Chen et al. 2001a) and MUC5AC protein
in glandular cells of COPD patients (Caramori
et al. 2009)—this has not been observed in CF
lungs. However, in neonatal wild-type and CF
piglets, both Muc5ac and Muc5b mucins are
expressed in goblet cells in the conducting
airway epithelium, whereas Muc5b, but not
Muc5ac, is expressed in glandular cells. Interest-
ingly, the submucosal glands of CF piglets have
Table 1. Human tissues (normal) expressing polymeric mucin glycoproteins
Tissue MUC2 MUC5AC MUC5B MUC6 MUC19 References
Salivary glands (sublingual) X a Zalewska et al. 2000
Nasal glands X Martinez-Anton et al. 2006
Nasal septum and
nasopharynx




X Rose and Voynow 2006;
Thornton et al. 2007
Airway submucosal glands X Rose and Voynow 2006;
Thornton et al. 2007
Stomach X X Corfield et al. 2000; Linden
et al. 2008




X X Sasaki et al. 2007
Pancreatic ducts X Reid et al. 1997b;
Hollingsworth 1999
Cervix X X X
(low)
Andersch-Bjorkman et al. 2007
Conjunctiva X
(low)
X c Spurr-Michaud et al. 2007
aMUC19 mucin glycoprotein is expressed in saliva from rats, horses, pigs, and cows, but was not detected in human saliva
(Rousseau et al. 2008).
bMuc5b is expressed in Clara cells of wild-type (WT) mouse airways under control conditions, and during development and
in mucus metaplasia (Zhu et al. 2008; Roy et al. 2011). Muc5ac is expressed during mucus metaplasia (Zuhdi Alimam et al.
2000; Zhu et al. 2008); however, the human MUC gene products expressed in healthy and inflamed human small airways
(bronchioles) remain to be identified.
cMUC5B appears to be expressed in lacrimal glands but was not detected in tears (Spurr-Michaud et al. 2007).
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reduced Muc5b immunostaining relative to
gland volume, suggesting that mucous cell de-
velopment is reduced and that airway changes
that begin during fetal life may contribute to CF
pathogenesis and clinical disease during post-
natal life (Meyerholz et al. 2010).
MUC5AC and MUC5B mucins are overpro-
duced in CF lung secretions (Kirkham et al.
2002), especially following exacerbations (Henke
et al. 2007). An earlier report that MUC5AC and
MUC5B mucin levels are decreased in CF spu-
tum (Henke et al. 2004) highlights the challenges
inherent in analyzing CF lung sputum. Early
studies in the field identified differences in levels
of mucins and the presence of DNA and inflam-
matory markers in CF sputum (Boat et al. 1976).
Biochemical studies show that CF lung mucins in
sputum are heterogeneous in size, likely reflect-
ing digestion of mucins by proteinases in CF spu-
tum (Rose et al. 1987). MUC5AC mucin is de-
graded by neutrophil elastase (Voynow et al.
1999; Henke et al. 2011), as is MUC5B mucin
(Henke et al. 2011). MUC2 mucin or peptides
are barely detectable in normal (Hovenberg
et al. 1996a,b) or CF sputum (Davies et al. 1999;
Kirkham et al. 2002), although MUC2 mRNA
is well expressed in CF bronchial explants and is
up-regulated by Pseudomonas aeruginosa lipo-
polysaccharide (Li et al. 1997) and other inflam-
matory mediators. Taken together, these data in-
dicate that inflammatory mediators and bacterial
byproducts in CF lungs contribute to the over-
production of mucins in vivo, as they do in vitro
(for review, see Rose and Voynow 2006).
Knowledge of CFTR genotypes has taught








CFTR + MUC5AC CFTR
Figure 2. Immunolocalization of CFTR, MUC5AC, and MUC5B in normal human airway epithelium. (Left
panel) Confocal microscopy overlay image of a human frozen bronchial section from a normal lung donor
immunostained with antibodies against MUC5AC (clone 45M1) and MUC5B (VNTR region). MUC5AC
expression is restricted to goblet cells of the surface epithelium, whereas MUC5B is expressed in the goblet cells
of the surface epithelium and predominantly in submucosal glands both in the ciliated ducts (CD) and acini
(GA) in a gradient pattern with the highest levels in the acini. Scale bar, 200 mm. (Inset) Goblet cells of the surface
epithelium show that MUC5B is present in the surface epithelium and can be coexpressed with MUC5AC. Scale
bar, 20 mm. (Center panel) Confocal microscopy image of a frozen section of human bronchus immunostained
with a CFTR antibody. Images represent an overlay of the differential interference contrast (DIC) (gray) and
CFTR immunofluorescence (red) confocal channels, and indicate that CFTR protein is mainly localized in the
apical membrane of ciliated cells of the surface epithelium and ciliated ducts; CFTR immunostaining is neg-
ligible in serous cells of the gland acini. Scale bar, 20 mm. (Only 20% of normal bronchial specimens display
CFTR immunostaining in glandular serous cells.) (Inset) Confocal image of coimmunostaining of CFTR and
MUC5AC in primary cultures of human bronchial epithelium indicating that CFTR is not immunolocalized in
goblet cells. Scale bar, 10 mm. (Images from Kreda et al. 2005; reproduced, with permission, from ASCB/
Molecular Biology of the Cell.) (Right panel) Confocal microscopy images of CFTR immunolocalization in
the gland acini of human nasal epithelium. CFTR is localized in the apical membrane of serous cells in
50% of normal nasal specimens (Kreda et al. 2005). Scale bar, 20 mm. SE, surface epithelium; CD, ciliated
duct; GA, gland acini.
S.M. Kreda et al.



















2010), but not enough to completely predict
phenotype and disease severity, which has re-
sulted in searches for genetic modifiers in CF
patients. A few mucin genes have now been
evaluated with regard to their variable number
of TR lengths (Guo et al. 2011). A significant
association of a 6.4-kb TR in the MUC5AC gene
is associated with severity of CF lung disease,
suggesting that this polymeric mucin gene
may be a genetic modifier for CF lung disease.
No strong associations were found for MUC1,
MUC2, or MUC7 mucin genes. Whether the
genes that encode the polymeric MUC5B or
the membrane-tethered MUC4 and MUC16
mucins are also genetic modifiers of CF lung
disease remains to be established.
IMPACT OF CFTR EXPRESSION ON
MUCUS PRODUCTION IN CF
Overview
One of the most important aspects of under-
standing the pathogenesis and pathophysiology
of CF with regard to the mucus problem in CF
involves understanding CFTR expression at the
cellular and tissue levels. The organs that show
pathophysiology in CF patients are those of
epithelial origin, especially mucosal epithelia
(Quinton 1990; Mall et al. 2004b; Kreda et al.
2005). As detailed below, CFTR expression and
function have been described in epithelial cells
of upper and lower respiratory tracts (Trezise
and Buchwald 1991; Engelhardt et al. 1992,
1994; Trezise et al. 1993; Kalin et al. 1999; Pen-
que et al. 2000; Carvalho-Oliveira et al. 2004;
Kreda et al. 2005); the gastrointestinal tract
(Trezise and Buchwald 1991; Tizzano et al.
1993; Manson et al. 1997; Kalin et al. 1999;
Mall et al. 2004b), including pancreatic glands
(Crawford et al. 1991; Marino et al. 1991; Trezise
and Buchwald 1991; Tizzano et al. 1993; Trezise
et al. 1993), liver and gallbladder (Tizzano et al.
1993; Yang et al. 1993); salivary glands (Trezise
and Buchwald 1991; Best and Quinton 2005);
and male and female reproductive tracts (Tre-
zise and Buchwald 1991; Tizzano et al. 1993,
1994b; Trezise et al. 1993). However, CFTR is
also expressed and functional in epithelia that
lack mucus secreting cells—for example, sweat
ducts (Quinton 1983, 1990; Cohn et al. 1991;
Kartner et al. 1992; Claass et al. 2000; Kreda and
Gentzsch 2011) and kidney (Jouret and Devuyst
2009)—but show ion transport abnormalities
in CF. Furthermore, CFTR expression has been
detected in non-epithelial tissues such as heart
(Davies et al. 2004), brain (Mulberg et al. 1998;
Robert et al. 2004), smooth muscle (Robert
et al. 2004), and lymphocytes (Yoshimura
et al. 1991), and the contribution of these sites
to epithelial organ damage and CF disease, al-
though underinvestigated, may be significant
(Tirouvanziam et al. 2002; Bruscia et al. 2009;
Hodges and Drumm 2009).
Although epithelial and non-epithelial tis-
sues show CFTR-associated chloride and HCO3
2
transport abnormalities in CF patients, the
most severe lesions responsible for CF morbid-
ity are the result of mucus-based obstructions
(often chronically infected) in the lumens of
organs that support epithelial gel-forming mu-
cin production (i.e., airways, intestine, and re-
productive organs) (Boat et al. 1989; Tizzano
and Buchwald 1995; Welsh et al. 1995). That
some mucus-producing organs do not show
obstructive or severe complications in CF (e.g.,
salivary and lacrimal glands) (Tizzano and
Buchwald 1995; Castagna et al. 2001) has ob-
scured the linkage of CFTR expression/defi-
ciency with mucus production/obstruction,
and ultimately, with organ failure. As a conse-
quence, several hypotheses have arisen to ex-
plain the relationship between CFTR deficiency
and mucus obstruction across different organs.
The hypotheses fall into two broad categories—
one represented by the concept that mucus ob-
struction and organ failure is a direct conse-
quence of epithelial CFTR deficiency, the other
that mucus obstruction and organ failure occur
secondarily to epithelial CFTR deficiency. The
hypothesis that CFTR is involved directly in
mucus production (i.e., mucin synthesis, post-
translation modifications, trafficking, secretion,
and/or postsecretion modifications) holds that
CFTR deficiency results in mucins with abnor-
mal physicochemical qualities, favoring luminal
accumulation, abnormal adhesion, and infec-
tion (Barasch et al. 1991; Barasch and al-Awqati
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1993; Zhang et al. 1995; Xia et al. 2005; Quinton
2010). However, this hypothesis has never been
unequivocally confirmed, as detailed below.
The second possibility, that CFTR is indi-
rectly related to mucus obstruction, has given
rise to several hypotheses. One is the “dehydra-
tion hypothesis,” in which mutated CFTR fails
to contribute to the ionic drive needed for ap-
propriate hydration of the mucus layer, result-
ing in thick mucus with concentrated mucins
that collapses onto the underlying epithelium as
a first step toward chronic infection and organ
disease (Matsui et al. 1998; Boucher 2007; Chen
et al. 2010). Another is the “innate immune
hypothesis” wherein mutated CFTR results in
abnormal mucus with diminished expression/
activity of epithelial antimicrobial molecules
important for homeostasis following inflam-
mation and infection, thereby contributing to
chronic infection and organ disease (Smith
et al. 1996; Zabner et al. 1998). When focused
on altered secretion of innate immune proteins
by the submucosal glands, this hypothesis is
termed “the serous cell malfunction hypothe-
sis” because airway serous cells require CFTR
for the secretion of the antimicrobial-rich fluid
elaborated by submucosal glands in response
to irritants. In CF, fluid secretion by these cells
is greatly diminished, resulting in airway mucus
that is thicker (Wine and Joo 2004; Ballard and
Spadafora 2007).
CFTR Expression
One of the most controversial aspects of CFTR
studies has been the elucidation of CFTR ex-
pression in non-CF and CF organs. The ratio-
nale for these studies has been that determining
the localization and levels of CFTR in different
organs will help to elucidate the pathogenesis of
CF and thus better direct the design of effective
therapies. For the last 20 years, many laborato-
ries using different experimental approaches
(i.e., expression and localization of CFTR
mRNA and protein and functional assessment
of ion channel activity) have pursued studies
producing some common findings, as well as
some more controversial results. In analyzing
the published data, it is necessary to take into
account the experimental design and the re-
agents used, in particular the CFTR antibodies
used to produce CFTR expression data in native
tissues by means of immunostaining and west-
ern blotting. For example, a few studies, which
produced controversial expression data in na-
tive tissues, used CFTR antibodies that were
subsequently reported to perform differently
according to tissue quality and histological
techniques (Claass et al. 2000; Kreda and
Gentzsch 2011). Not all antibodies are created
equal, and rigorous controls and independent
techniques should be used in parallel to detect
low levels of CFTR protein expression in native
tissues. Currently, highly sensitive and specific
CFTR antibodies are readily available through
the North America CF Foundation, and detec-
tion techniques are much improved, which
has allowed scientists in the field to confirm or
challenge expression data reported earlier. In
the next sections, some of the key findings on
CFTR mRNA and protein expression in the
most severely affected organs are discussed
from the perspective of the “mucus problem.”
CFTR Expression in Goblet Cells of the
Respiratory and Gastrointestinal Tracts
Notably, the most severe and life-threatening
complications of CF disease are associated
with aberrant mucus that obstructs and infects
the airway and intestinal lumens, but the func-
tional relationships between CFTR and goblet
cells in those organs have not been completely
defined. With the exception of a few immuno-
staining studies reporting CFTR expression in
goblet cells of airway and intestinal tissues (Jac-
quot et al. 1993; Dray-Charier et al. 1995; Kalin
et al. 1999), most studies fail to detect signifi-
cant levels of expression (or channel activity) in
goblet cells. As we review below, CFTR expres-
sion/activity, instead, is mainly localized apical-
ly not to MUC5AC-expressing goblet cells, but
to the neighboring epithelial cells (Fig. 2, center
panel) known to be involved in ion and fluid
transport. Thus, aberrant mucus production
appears to be secondary to defective, CFTR-
driven ion composition and/or fluid volume
in CF epithelia (Kreda et al. 2010; Quinton
S.M. Kreda et al.



















2010; Wine et al. 2011). Yet, evidence of chemi-
cal differences (e.g., terminal glycosylation with
regard to sulfation, sialylation, fucosylation,
and carbohydrate composition) in CF mucins
(Cheng et al. 1989; Barasch et al. 1991; Barasch
and al-Awqati 1993; Zhang et al. 1995; Xia et al.
2005) might implicate a direct role for CFTR
in the posttranslational processing of mucins
(see section below: Mucin Glycosylation and
CF). Because the glycosylstransferases requisite
for O-glycosylation are predominant in goblet
and mucous cells, it would imply that CFTR
activity is present in intracellular compartments
and is necessary for proper mucin biosynthesis.
Emerging technical advances in the field of mu-
cin chemistry and goblet cell and mucin granule
isolation will allow us to address these impor-
tant questions in the near future; however, as the
following subsections indicate, the available
evidence suggests that CFTR is absent from
mucin-secreting cells (Fig. 2, center and right
panels), with the exception of pancreatic and
hepatobiliary ductal epithelia whose simple, cu-
boidal epithelial cells express CFTR and are re-
sponsible for both transepithelial ion and fluid
transport and mucin secretion (Hollingsworth
1999; Kuver et al. 2000; Sasaki et al. 2007).
CFTR Expression in the Upper and
Lower Respiratory Tracts
CFTR transcripts are expressed during develop-
ment in the pseudoglandular epithelium of the
human fetal primordial lung (Tizzano et al.
1994a). Subsequently during fetal development,
CFTR expression decreases in the alveoli and is
gradually restricted to the surface epithelium in
the large and small airways, and not detected in
fetal submucosal glands (Tizzano et al. 1993,
1994a; Trezise et al. 1993). In contrast, in the
neonatal period, CFTR mRNA expression de-
creases in the surface of the conductive airway
epithelia but appears gradually in the submu-
cosal glands (Tizzano et al. 1993, 1994a; Trezise
et al. 1993). In the adult lung, although the level
of CFTR mRNA expression is lower than in the
fetal lung, mRNA is observed in the surface ep-
ithelium of nose, trachea, bronchi, and proxi-
mal bronchioles, while being scarce in the distal
bronchioles and alveoli (Engelhardt et al. 1994;
Kreda et al. 2005). In the airway submucosal
glands, CFTR mRNA expression appears to de-
crease distally toward the acini (Engelhardt et al.
1994; Kreda et al. 2005). Interestingly, this pat-
tern of CFTR mRNA expression appears to be at
odds with CF pathogenesis. For example, CFTR
expression is highest during fetal life, but CF
lungs are mostly normal at birth; similarly, CF
lung disease develops in the infant and is the
primary cause of mortality of young and adult
CF patients (Boat et al. 1989), despite low levels
of CFTR expression at these ages. Moreover,
submucosal gland hyperplasia is one of the ear-
liest pathogenic changes, yet CFTR expression
in the glands is seen only after birth (Tizzano
et al. 1994a).
Immunolocalization of CFTR Protein Does
Not Correlate with CFTR mRNA in Lung
Tissues
Localization of CFTR protein is hindered by the
capability of CFTR antibodies to detect low lev-
els of protein expressed in adult human lung
tissues. Consequently, CFTR expression data,
by means of immunostaining, can vary accord-
ing to the CFTR antibodies used and do not
always reflect mRNA expression (Kreda and
Gentzsch 2011). For example, an early study
by Engelhardt and collaborators, using a poly-
clonal antibody that recognizes the carboxyl ter-
minus of CFTR, describes CFTR protein expres-
sion being associated mainly with the apical
membrane of the serous cells in the submucosal
glands, although mRNA expression was high in
the superficial and gland ductal epithelia (En-
gelhardt et al. 1992, 1994). In contrast, a subse-
quent study by Kreda and collaborators, using
very sensitive monoclonal antibodies recogniz-
ing the NBD2 domain of CFTR (Mall et al.
2004b), describes CFTR protein expression
mainly in the apical membrane of all ciliated
cells in the epithelium lining the nose and all
airway regions, including submucosal gland
ducts; however, CFTR protein was not obvious-
ly expressed in the acinar cells of bronchial sub-
mucosal glands (Kreda et al. 2005). Interesting-
ly, CFTR was detected in the glandular serous
CFTR, Mucins, and Mucus Obstruction



















cells in 20% of normal bronchial specimens
(Fig. 2, center panel) and in 50% of normal
nasal specimens (Fig. 2, right panel) (Kreda
et al. 2005). Despite both studies (Engelhardt
et al. 1992; Kreda et al. 2005) showing a similar
pattern of localization of CFTR transcripts in
the human lung, the CFTR protein immuno-
localization data are very different. The distri-
bution of immunostaining signal described by
Kreda et al. (2005) corresponds with the pattern
of mRNA localization in the lung, suggesting
that CFTR expression is important in the sur-
face epithelia and that it decreases distally to-
ward the acinar structures in the submucosal
glands. However, in the airway glands, CFTR
activity appears to be more important in the
acinus than in the proximal ducts (Joo et al.
2002; Ballard and Inglis 2004; Ballard and Spa-
dafora 2007; Wu et al. 2007b; Choi et al. 2009;
Wine et al. 2011). Thus, one conclusion of these
studies is that expression of CFTR gene prod-
ucts may not always predict accurately how crit-
ical CFTR activity might affect the physiological
functions of a particular tissue or organ. Addi-
tionally, these data stress the need to validate
immunostaining findings with alternative ap-
proaches to identify CFTR expression (i.e.,
western blotting and channel activity).
At the cellular level, most localization stud-
ies identify CFTR protein expression in the api-
cal plasma membrane of ciliated cells in nasal
and airway epithelia (Puchelle et al. 1992; Bre-
zillon et al. 1995; Kalin et al. 1999; Penque et al.
2000; Carvalho-Oliveira et al. 2004; Kreda et al.
2005; Kreda and Gentzsch 2011) and the acinar
serous cells of submucosal glands (Fig. 2) (En-
gelhardt et al. 1992; Kalin et al. 1999; Kreda et al.
2005), and more recently, in isolated type II
alveolar cells (Brochiero et al. 2004; Bove et al.
2010). Although a few studies indicated CFTR
localization in airway goblet cells (Jacquot et al.
1993; Kalin et al. 1999), most laboratories did
not detect CFTR expression in mucous/goblet
cells in human lung tissues (Engelhardt et al.
1992, 1994; Puchelle et al. 1992; Brezillon et al.
1995; Kalin et al. 1999; Kreda et al. 2005; Kreda
and Gentzsch 2011), in primary cultures of air-
way epithelial cells (Kreda et al. 2005; Cholon
et al. 2010), or in mucin-secreting cell lines
derived from airway epithelia, for example,
SPOC1 cells (Abdullah et al. 1997) and Calu-3
cells (Kreda et al. 2007). Calu-3 is an adenocar-
cinoma cell line that differentiates into two dis-
tinctive cell types: one that expresses high levels
of functional CFTR in the apical membrane,
and another that expresses MUC5AC mucins
(Kreda et al. 2007). CFTR was not detected in
mucin granule membranes isolated from Calu-
3 cells (Kreda et al. 2010; SM Kreda and J Sesma,
unpubl.), even though Calu-3 cultures do ex-
press high levels of CFTR (Shen et al. 1994;
Kreda et al. 2007). Thus, CFTR expression and
channel activity in mucosal epithelia appear to
be associated with cell types involved in ion/
fluid transport rather than with mucin-produc-
ing cells in the human lung.
CFTR Expression in Human
Gastrointestinal Organs
Unlike the lung, the pattern of CFTR mRNA
expression in the gastrointestinal track is similar
in the fetus and adult, suggesting that CFTR
performs similar functions in the fetal and adult
gastrointestinal tracts (Crawford et al. 1991;
Trezise et al. 1993; Strong et al. 1994) and is
consistent with the fact that severe gastrointes-
tinal disease is the initial pathological feature in
CF (Park and Grand 1981; Boat et al. 1989).
Already during fetal development, and continu-
ing through life, high levels of CFTR mRNA
expression are observed in the epithelium of
all gastrointestinal regions (Tizzano et al. 1993;
Strong et al. 1994). CFTR mRNA expression is
highest in the duodenum and decreases along
the small intestine. It is lowest in the colon and
presents as a decreasing gradient of expression
along the crypt–villous axis, with CFTR mRNA
being lowest in the luminal half of the villus in all
intestinal regions (Tizzano et al. 1993; Trezise
et al. 1993; Strong et al. 1994). High levels of
CFTR mRNA are also observed in the Brunner’s
glands (Strong et al. 1994) and in the ductal and
centroacinarcellsat laterdevelopmentstages and
in the adult (Tizzano et al. 1993; Trezise et al.
1993; Strong et al. 1994). In the liver, CFTR
mRNA is localized to the epithelia of bile ducts
and ductules, whereas in the gallbladder, high
S.M. Kreda et al.



















levels of CFTR mRNA are observed in the epi-
thelium, with no expression detected in the he-
patocytes or bile canaliculi (Tizzano et al. 1993;
Trezise et al. 1993; Strong et al. 1994).
Importantly, the pattern of CFTR mRNA
expression is indicative of the pathological
changes observed in the gastrointestinal track
of affected CF individuals (Crawford et al.
1991; Tizzano et al. 1993; Trezise et al. 1993;
Strong et al. 1994). Meconium ileus and intes-
tinal mucus-based obstruction are among the
earliest manifestations of CF (Duchatel et al.
1993) and may reflect a failure in utero to pro-
teolytically digest swallowed and sloughed pro-
teins, which may include mucins. Distal intes-
tinal mucus-based obstruction occurs in .20%
of adult patients. Ductal obstruction and dila-
tion in the Brunner’s glands, the crypts of Lie-
berkuhn, and the pancreas have been observed
in affected fetuses, while pancreatic insufficien-
cy requires oral enzyme supplementation in
85% of CF patients. Similarly, liver disease
characterized by excessive accumulation of mu-
cus in bile ducts and ductules is observed al-
ready early in life and evolves in focal biliary
fibrosis and cirrhosis, affecting 20%–50% of
all CF patients (Park and Grand 1981; Boat
et al. 1989; Tizzano et al. 1993; Yang et al. 1993).
Immunolocalization of CFTR Protein
Correlates with CFTR mRNA Findings
in Gastrointestinal Tissues
As in the lung, the quality of the antibodies and
techniques used must be taken into account in
analysis of CFTR immunolocalization data in
gastrointestinal tissues (Fig. 2). In the human
stomach, CFTR immunolocalizes to the epithe-
lium but at low levels (SM Kreda, unpubl.). In
the intestine, CFTR immunolocalizes specifi-
cally to the apical membrane of enterocytes in
the crypts and villi of the small intestine (Mall
et al. 2004b; Kreda and Gentzsch 2011) and the
crypts of the jejunum and colon (Crawford et al.
1991; Mall et al. 2004b); CFTR protein immu-
nostaining is more prominent in the base de-
creasing toward the tip of the crypts (Mall
et al. 2004b; Kreda and Gentzsch 2011), follow-
ing the pattern of CFTR mRNA expression. In
the pancreas, liver, and gallbladder, CFTR im-
munostaining also reflects the pattern of mRNA
expression, with CFTR protein being detected
chiefly in the apical membrane of non-mucous
cells (Crawford et al. 1991; Marino et al. 1991;
Cohn et al. 1993; Yang et al. 1993). Although
goblet cell hyperplasia is present in all gastroin-
testinal regions and mucus obstruction is a fea-
ture of gastrointestinal CF disease (Park and
Grand 1981; Boat et al. 1989; Tizzano et al.
1993), most studies have failed to detect CFTR
immunostaining associated with goblet cells in
the GI epithelia, even using epitope retrieval and
other signal-enhancing techniques (Mall et al.
2004b; Kreda and Gentzsch 2011). A few studies
reported CFTR immunostaining associated spe-
cifically with intracellular organelles of goblet
cells, in all intestinal regions (Kalin et al. 1999)
and in the gallbladder (Kuver et al. 2000); how-
ever, the antibodies used in these studies have
been reported to produce unexpected results in
human tissues (Claass et al. 2000). Moreover,
CFTR is immunolocalized to the apical mem-
brane of enterocytes in murine intestine, and no
CFTR expression was observed in goblet cells in
the proximal and distal intestine (Jakab et al.
2011). The selective expression of CFTR in the
enterocytes supports a role of CFTR in regulat-
ing ion and fluid transport in the human and
rodent intestine (Garcia et al. 2009).
CFTR Expression in the Reproductive Organs
Virtually all CF males are azoospermic because
of atrophy and obstruction of the epididymis,
vas deferens, and seminal vesicles. These path-
ological changes have often been interpreted as
a secondary lesion to mucus-based obstruction
of the epididymis and vas deferens ductal sys-
tem (Tizzano et al. 1994b). Accordingly, CFTR
mRNA is expressed mainly in the ductal epithe-
lial cells of the epididymis in the human male
fetus, newborn, and infant (Trezise and Buch-
wald 1991; Tizzano et al. 1993, 1994b). In
adults, the epithelium of the epididymis and
vas deferens shows a high level of CFTR
mRNA expression, whereas low mRNA expres-
sion is observed in testis, prostate, or seminal
vesicles throughout life (Tizzano et al. 1994b).
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CFTR immunostaining reflects mRNA expres-
sion and is observed at the luminal surface of
epithelial cells of the efferent ducts and the ep-
ididymis (Hihnala et al. 2006; Kujala et al.
2007). In the seminal vesicles and prostate, no
immunostaining is observed in the glandular
epithelium, but strong labeling for CFTR is pre-
sent on the luminal surface of the ductal epithe-
lium (Hihnala et al. 2006; Kujala et al. 2007).
CFTR is also immunolocalized to the equatorial
segment of human and mouse spermatozoids
(Hihnala et al. 2006; Kujala et al. 2007; Xu et al.
2007). More studies are needed to understand
the link between CFTR deficiency and the path-
ological changes in the CF male reproductive
tract.
Females with CF have reduced fertility, but
the underlying causes are not well understood.
Infertility has been proposed to be mainly a con-
sequence of abnormally thick, dense cervical
mucus that presents a barrier for sperm penetra-
tion and transport to the egg (Brugman and
Taussig 1984; Tizzano et al. 1994b; Hodges
et al. 2008). However, altered ion and fluid trans-
port (due to CFTR deficiency) throughout the
female reproductive track, endocrine abnor-
malities, and menstrual irregularities may also
account for infertility in women and mouse
models with CF (Brugman and Taussig 1984;
Tizzano et al. 1994b; Hodges et al. 2008; Chan
et al. 2009). Expression of CFTR mRNA is evi-
dent in the female fetus after the third trimester
in the epithelium of the uterine cervix and the
Fallopian tube (Tizzano et al. 1993). In new-
borns and infants, CFTR mRNA expression is
found at high, moderate, and low levels in the
epithelium and glands of the cervix, the Fallopi-
an tubes, and the endometrium, respectively;
whereas in adults, a high level of mRNA expres-
sion is detected in the cervix and to a lesser de-
gree in both endometrium and Fallopian tubes;
no expression was observed in ovaries at any age
(Tizzano et al. 1994b). By immunostaining,
CFTR has been observed in the apical surface
of uterine and oviduct epithelial cells involved
in fluid secretion (Rochwerger and Buchwald
1993). In the Fallopian tubes, CFTR is localized
specifically to the apical membrane of epithelial
cells (Ajonuma et al. 2005). CFTR immuno-
staining is also present in the apical membrane
of fluid-secreting cells of the endocervix (SM
Kreda, unpubl.). The levels of CFTR mRNA ex-
pression change during the menstrual and (es-
trous) cycle in the female reproductive track
(Hodges et al. 2008; Chan et al. 2009). Whether
these changes correlate with the fluctuations in
levels of specific mucins and alterations in mu-
cin glycosylation and physical properties that
occur during estrous has not yet been evaluated
as far as we are aware, but may be informative in
understanding the impact of CFTR on mucins
and mucosal components in an epithelial tract
that is not typically infected in CF.
CFTR Expression in the Organs of
CF Patients
The pattern of expression of mRNA transcripts
for DF508 CFTR (the most frequent mutation
in the Caucasian population) and wild-type
CFTR is similar in human tissues, indicating
that there is no significant defect at the level of
mRNA expression in (DF508) CF tissues (Trap-
nell et al. 1991; Engelhardt et al. 1992). Howev-
er, the protein expression and localization of
mutated CFTR, in particular DF508 CFTR,
have produced different results depending on
the antibodies used. For example, most CFTR
antibodies recognize wild-type CFTR protein at
the apical membrane of epithelial cells in sweat
ducts from normal but not from DF508 homo-
zygous individuals (Quinton 1990; Cohn et al.
1991; Kartner et al. 1992; Kalin et al. 1999;
Claass et al. 2000; Kreda and Gentzsch 2011),
in agreement with the concept that the absence
of protein in the apical membrane of epithelial
cells in DF508 homozygous tissues reflects lack
of fully glycosylated CFTR protein and channel
activity in those tissues (Cheng et al. 1990;
Quinton 1990; Cohn et al. 1991; Marino et al.
1991; Puchelle et al. 1992; Zeng et al. 1997; Mall
et al. 2004b; Kreda et al. 2005; Kreda and
Gentzsch 2011; Thomas and Lukacs 2012). In
contrast, a few immunostaining studies report-
ed that localization of human DF508 CFTR did
not differ from wild-type CFTR in airway and
intestinal tissues (Dray-Charier et al. 1995; Du-
puit et al. 1995; Kalin et al. 1999; Penque et al.
S.M. Kreda et al.



















2000). However, with the availability of CFTR
antibodies of high sensitivity and specificity
and sensitive confocal microscopy techniques,
these issues have been revisited. In these studies,
DF508 CFTR protein was not detected in the
apical membrane of epithelial cells in native tis-
sues and primary cell cultures from human
nose and lung and intestine (Mall et al. 2004b;
Kreda et al. 2005; Kreda and Gentzsch 2011), as
originally observed in the sweat duct of CF pa-
tients (see above). These observations reflect the
loss of processing and trafficking of CFTR that
occurs in mutated CFTR (see Riordan 2012).
MUCIN OVERPRODUCTION IN CF
Overview
Several processes can account for mucin over-
production and increased mucin levels in the
human respiratory tract, including hypersecre-
tion of mucins, proteolytic cleavage of mem-
brane-tethered mucins, up-regulation of MUC
gene expression, and epithelial remodeling
by goblet cell hyperplasia/metaplasia and/or
glandular hyperplasia (for review, see Rose and
Voynow 2006). A network of genes that tran-
scriptionally mediate goblet cell metaplasia/hy-
perplasia in murine and human epithelium is
emerging (Chen et al. 2009). In CF lung epithe-
lial, patches of goblet cell hyperplasia were ob-
served (Voynow et al. 2005). In contrast, goblet
cell hyperplasia is not observed in CF bronchial
biopsies, although an increase in goblet cell size
in CF tissue, as well as a fourfold increase in
submucosal gland volume, was reported (Hays
and Fahy 2006). It is worth noting, however, that
goblet cell size is not necessarily a good markerof
mucin production, because a cell in which mu-
cin synthesis is elevated could be secreting mu-
cins at an equal rate. In fact, at this point, we have
no idea of the cellular mechanisms regulating
the quantity of mucin stores in goblet cells.
In the murine conducting airway epitheli-
um, allergenic sensitization and challenge or the
Th2 cytokine IL13 induce mucus cell metapla-
sia, and thus expression of Muc5ac in goblet
cells (Zuhdi Alimam et al. 2000). It is now clear-
ly evident that murine lung secretory cells ex-
press Muc5b at baseline conditions and trans-
differentiate to goblet cells that express Muc5b
and Muc5ac in response to allergenic sensitiza-
tion and challenge (Zhu et al. 2008). Based on
these studies and studies on mucin gene expres-
sion during development of mouse lungs (Roy
et al. 2011) and mucin gene knockout studies (C
Evans, unpubl.), emerging paradigms are that
Muc5b is an intrinsic component of homeostat-
ic mucosal defense in murine lungs and that
both Muc5ac and Muc5b genes can be up-regu-
lated in vivo by mediators activated during in-
flammation and infection. The relevance of
these concepts to human lung diseases, espe-
cially CF, will unfold further as studies are per-
formed in Cftr ferrets and pigs, which have
abundant submucosal glands and thus more
closely resemble human airways.
A suggestion that appears to arise periodi-
cally is that it is the exocytic secretion of mucins
that is affected in CF. The existing data, however,
do not support this notion. Basal- and agonist-
stimulated mucin secretion are not different in
primary cultures of airway epithelial cells from
non-CF and CF individuals (Fig. 3A) (Lethem
et al. 1993) or from non-CF sources treated with
CFTR inh172, a potent CFTR inhibitor (Fig. 3B)
(Hodges and Drumm 2009). Another sugges-
tion, discussed briefly below (see section on Mu-
cin Secretion and Regulation), in favor for sev-
eral years, held that a dysfunctional CFTR was
responsible for changes in glycosylation, sulfa-
tion, and sialylation of CF mucins. However, this
would require expression of CFTR in goblet
cells, which is not supported by current data,
as addressed above. The current paradigm is
that the various processes that drive mucin over-
production and hypersecretion are directed to a
large extent by inflammation and are predomi-
nantly impacted by mechanisms that drive mu-
cin gene regulation and mucin secretion. These
are independent processes, although the terms
“mucin production” and “mucin secretion” are
still sometimes used interchangeably in the lit-
erature. Understanding how mucin gene regu-
lation and secretion are modulated during in-
flammation in CF airways is a fundamental
question that remains to be answered. Thus, re-
cent information on mucin gene regulation and
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mucin secretion potentially relevant to our un-
derstanding of CF lung disease is reviewed be-
low.
Mucin Gene Regulation
Multiple stimuli (bacterial, viral, inflammato-
ry) induce overproduction of polymeric mucins
by up-regulating expression of polymeric mucin
genes. This regulation is complex and can be
both cell and mucin gene specific. Transcrip-
tional up-regulation of MUC gene expression
is activated following binding of mediators to
membrane receptors on secretory cells, result-
ing in activation of various signal transduction
pathways and transcription factors that then
translocate to the nucleus and bind to cis-sites
on MUC gene promoters. Typically, studies ini-
tially use lung epithelial cancer cell lines (NCI-
H292 and A549) and/or immortalized lung
epithelial cell lines, for example, HBE1 cells
(Yankaskas et al. 1993) or 16HBE cells (SV-
40 virus-transformed, immortalized HBE cell
lines) (Bruscia et al. 2002). To assess the rele-
vance of observations, findings are then evalu-
ated in primary differentiated human bronchi-
al epithelial (HBE) or human nasal epithelial
(HNE) cells.6 These latter cells differentiate to
a polarized epithelium with ciliated, goblet, and
basal cells when grown under air–liquid inter-
face conditions and are model systems that mor-
phologically recapitulate the conducting epi-
thelium of the respiratory tract (Wu et al.
1990; Kondo et al. 1993; Gruenert et al. 1995).
Some mechanisms present in lung cancer cell
lines are lacking in HBE cells, and instances
are pointed out below. This reinforces the im-
portance of validating results obtained in cancer
or immortalized cell lines with differentiated
HBE cells or animal models that reflect human
airways when investigating therapies for mucus
overproduction. In the sections below, the ex-
perimental cell types used are stated, rather than
the generic term “lung epithelial cells.”



































Figure 3. Mucin secretion in human bronchial epithelial cell cultures from healthy (normal) and CF individuals
(A), and from Calu-3 cells exposed to CFTRinh-172 (B). Mucin secretion, assessed as described in Abdullah et al.
(2012) and Kreda et al. (2007), was not affected in either case. The data are expressed as the mean + S.E.: HBE
cell culture data (LH Abdullah and CW Davis, unpubl.) (n ¼ 6); Calu-3 cell data (S Kreda, unpubl.) (n ¼ 3).
a.u., arbitrary units.
6Here these model systems are referred to as differentiated
HBE or HNE cells.
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Most of the literature with regard to me-
diators that increase MUC2, MUC5AC, and
MUC5B gene expression from 1995 to 2005 was
recently reviewed (Rose and Voynow 2006), and
schematics identifying the impact of these path-
ways on specific cis-sites in the promoters of
MUC2, MUC5AC, and MUC5B genes (Thai
et al. 2008) or the MUC5AC gene (Voynow
and Rubin 2009) have been published. This sec-
tion attempts to update and integrate in-
formation recently reported and focuses on reg-

























Figure 4. MUC5AC gene expression is transcriptionally regulated by various mediators and pathways. The figure
depicts mediators, receptors, and cis-sites reported since earlier reviews on regulation of MUC5AC gene expres-
sion (Rose and Voynow 2006; Thai et al. 2008; Voynow and Rubin 2009). Each reference is color-coded by arrows.
(Red) IL1b and IL17A induce MUC5AC expression by activation of the NFkB cis-site at 23594/23582 bp.
Direct binding of the NFkB p50 subunit was observed in HBE1 cells (Fujisawa et al. 2009). (Blue) PGF2a signals
through the prostaglandin F receptor (FP), which is coupled to the Gq protein to activate PKC, which then
signals through an MEK, ERK, RSK pathway. RSK translocates to the nucleus after phosphorylation and
activates CREB to bind to the CRE cis-site (2878/2871) to up-regulate MUC5AC expression in differentiated
HBE cells and NCI-H292 cells. A model summarizing the mechanisms whereby prostaglandins and IL1b induce
MUC5AC overexpression has been reported (Chung et al. 2009). (Pink) CREB binds maximally to the CRE cis-
site in the MUC5AC promoter 2 h after IL1b exposure to A549 or differentiated HBE cells (YA Chen, AM
Watson, LM Garvin, et al., unpubl.). (Orange) PMA activates the PKC isoforms d and u, resulting in activation of
matrix metalloproteinase (MMP) and secretion of TGFa, which binds to its cognate receptor EGFR. EGFR
activates the MEK/ERK1/2 pathway to activate Sp1, which binds to three Sp1 sites (2192/263) in the
MUC5AC promoter. Similar results were obtained in H292 cells (Hewson et al. 2004) and in differentiated
HBE and HBE1 cells (Yuan-Chen et al. 2007). (Green) ATP exposure to H292 cells induces MUC5AC expression
by activating PLCb3, which, in turn, activates Akt to signal through ERK or p38 to activate RSK, thereby
activating CREB and c-Ets1 binding to the CRE (2889/2869) and c-Ets1 (2938/2930) sites in the MUC5AC
promoter (Song et al. 2008). (Purple) Neuregulin 1b1 (NRG1b1) signals through the ERB2/ERB3 heterodimer
receptor to activate three different pathways: p38, ERK1/2, and PI3K, which signals through Akt to up-regulate
MUC5AC gene expression in differentiated HBE cells (Kettle et al. 2010).
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(Fig. 5) genes, which account for mucin over-
production in human lungs.
Transcriptional Regulation of Secretory
Mucin Genes
Ligand binding to cognate membrane recep-
tors—for example, the epidermal growth factor
receptor (EGFR, i.e., ErbB1, a member of the
ErbB family of receptor tyrosine kinases),
IL1R1, FP (Prostaglandin F receptor)—activates
specific signal transduction pathways many
of which converge or interact (Figs. 4 and 5).
This results in nuclear translocation and/or
phosphorylation of specific transcription fac-
tors, for example, CREB (cyclic AMP response
element-binding), NFkB (nuclear factor k-
light-chain-enhancer of activated B-cells), or
Sp1 (specificity protein 1), which bind to spe-
cific cis-sites on polymeric MUC gene promot-
ers. A predominant mechanism for regulating
MUC2 and MUC5AC gene expression is via ac-
tivation of EGFR, which results in activation of
extracellular signal-related kinases (ERK)1,2
(Takeyama et al. 1999; Lemjabbar and Basbaum
2002). Recent data show that the TGFa-induced
up-regulation of MUC5AC gene expression in




















Figure 5. MUC5B gene expression is transcriptionally regulated by various mediators and pathways. (Red) IL1b
and IL17A induce MUC5B gene expression by activation of the NFkB cis-site at 22921/22909 bp in the
MUC5B promoter. Direct binding of the NFkB p50 subunit was observed by ChIP in HBE1 cells (Fujisawa
et al. 2011). (Orange) PMA activates PKCd, which signals through Ras to activate MEKK1, which then signals
through either a p38 pathway or the JNK pathway to phosphorylate Sp1, which binds to the Sp1 site at
2184/2196. The Sp1 cis-site (2144/2122) functions to maintain basal regulation of MUC5B in differentiated
HBE cells and in HBE1 cells (Wu et al. 2007a). (Purple) NRG1b1 increases MUC5B gene expression in
differentiated HBE cells by signaling through the ErbB2/ErbB3 heterodimer receptor, which then signals
through three different pathways including p38, ERK1/2, and PI3k. PI3k goes on to activate Akt (Kettle et al.
2010).
S.M. Kreda et al.



















activated ERK1,2 pathway and also by ERK ac-
tivation and secretion of CCL20. The latter
mechanism activates the G-protein-coupled
receptor CCR6, resulting in metalloprotease
cleavage of EGFR pro-ligands and activation of
MUC5AC gene expression. However, this is not a
functional mechanism in primary differentiated
HBE cells because they do not express CCR6 in
vitro (Kim et al. 2011).
Neuregulin (NRG) 1b1, a member of the
neuregulin growth factor family, binds to
ERB2/ERB3 receptors, but not ERB4 or EGFR,
in differentiated HBE cells, resulting in up-reg-
ulation of both the MUC5AC and MUC5B genes
by activation of PI3K, p38, and Akt (Kettle et al.
2010). The activated transcription factors and
cis-sites on the MUC5AC and MUC5B promot-
ers to which they bind were not identified. Cig-
arette smoke also up-regulates expression of
MUC5AC in 16HBE cells through the neuregu-
lin 1b/ERB3 pathway (Yu et al. 2011). In con-
trast, in differentiated HBE cells, cigarette smoke
up-regulates monocyte chemotactic protein-1,
which increases expression of both MUC5AC
and MUC5B genes via a cascade initiated by li-
gand/receptor (CCR2B) interactions and activa-
tion of PLCb/PKC/MAPK (Monzon et al. 2011).
PGF2a binds to FP, which couples to the Gq pro-
tein to activate PKC, resulting in signaling
through the MEK/ERK/RSK pathway and acti-
vation of CREB to induce MUC5AC expression
in differentiated HBE cells (Chung et al. 2009).
Double-stranded RNA (Zhu et al. 2009) and
rhinovirus (RV) (Hewson et al. 2010) up-regu-
late MUC5AC expression in NCI-H292 cells
through serially linked signaling cascades that
result in activation of the EGFR-ERK pathway.
This may reflect the exaggerated EGFR response
in H292 cells (Kim et al. 2011) as RV up-regu-
lates MUC5AC expression via a Src/MEK/NFkB
pathway in primary tracheal cells (Inoue et al.
2006). Understanding how RV up-regulates se-
cretory mucin gene expression may prove im-
portant in understanding the response of lung
epithelial cells to virally induced exacerbations,
which are clinically relevant in CF and asthma.
Bacterial products produced by the Gram-
negative bacterium Pseudomonas aeruginosa
predominate in CF airways and can directly me-
diate lung mucin overproduction. P. aeruginosa
lipopolysaccharide (LPS) was the first mediator
shown to transcriptionally up-regulate expres-
sion of two secretory mucin genes—MUC2 (Li
et al. 1997) and MUC5AC (Li et al. 1998)—in
lung epithelial cells. Recently, the redox-active
virulence factor pyocyanin produced by Pseudo-
monas PAO1 and other strains has been shown
to increase MUC5AC and MUC2 mRNA and
protein abundance in NCI-H292, but not in
BEAS-2B, IB3-1, or 16BHE14o-, cells. PAO1
strains that express pyocyanin but lack genes
that encode LPS, flagellum, or pilus increase
MUC5AC and MUC2 mRNA levels (Rada et al.
2011), raising the possibility that commercial
preparations of LPS used in earlier studies con-
tained pyocyanin and that pyocyanin, rather
than LPS or other bacterial components, is re-
sponsible for inducing MUC2 and MUC5AC
gene expression during bacterial challenges.
Pyocyanin-activated intracellular reactive oxy-
gen species (ROS) and expression array analyses
of NCI-H292 cells showed that it also induced
expression of mediators potentially relevant to
CF lung disease, including IL8, IL1b, and TNFa
(Rada et al. 2011). ROS production has also
been shown to increase expression of MUC5AC
mRNA and protein, as well as the pro-inflamma-
tory mediators IL-8and IL1b (but not TNFa), in
NCI-H292 cells following exposure to Naegleria
fowleri, an amoeboflagellate that invades the
olfactory mucosa to access the central nervous
system (Cervantes-Sandoval et al. 2009).
Neutrophils, the predominant inflammato-
ry cells in CF airways, secrete neutrophil elastase,
which was initially shown to increase MUC5AC
gene expression both posttranscriptionally in
A549 and differentiated HBE cells (Voynow
et al. 1999) and transcriptionally in H292 cells
(Kohri et al. 2002). Defensin human neutrophil
peptide-1 (HNP-1), an antimicrobial peptide
secreted by neutrophils and present at high con-
centrations in the airway fluid of CF patients,
also increases levels of MUC5AC mRNA and
protein in NCI-H292 cells, and like LPS, induces
phosphorylation of ERK1/2 (Ishimoto et al.
2009).
Interleukin (IL) 17 cytokines and receptors
are of considerable interest in CF because they
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modulate neutrophil recruitment to the lungs
and host defense mechanisms against Gram-
negative bacteria like Pseudomonas. IL17 cyto-
kines are elevated in CF sputum (McAllister
et al. 2005; Decraene et al. 2010) and in neutro-
phils in CF lungs (Brodlie et al. 2011). IL17
cytokines signal through IL17R, which is local-
ized to basal cells in the differentiated HBE sys-
tem (McAllister et al. 2005). Because IL17R is
not expressed in secretory cells in the differen-
tiated HBE system (McAllister et al. 2005), the
mechanism whereby IL17 signaling is activated
in secretory cells remains unclear. Nevertheless,
IL17A increases MUC5AC (Fujisawa et al. 2009)
and MUC5B (Fujisawa et al. 2011) gene expres-
sion in differentiated HBE cells through activa-
tion of NFkB and binding of the NFkB subunit
p50 at position 23594/23582 in the MUC5AC
promoter and at 2921/22909 in the MUC5B
promoter. The Th2 cytokines IL4, IL9, and IL13
do not increase MUC5AC mRNA expression in
CF sinus mucosal tissues following a 24-h ex-
posure, although they do increase expression of
hCLCA1 (Hauber et al. 2010), a secretory gran-
ule membrane protein. These data support the
concept that the TH2 cytokines IL4 and IL13 do
not directly mediate MUC5AC mucin gene ex-
pression but, rather, impact the pathways that
lead to formation of secretory granules in goblet
cells, indirectly resulting in increased MUC5AC
levels in respiratory tract tissues.
The CREB transcription factor is emerging
as a major player in up-regulating MUC5AC
gene expression (Fig. 4), which may have impor-
tant clinical implications for the management
of airway mucus overproduction in CF. There is
a CRE cis-site (2878/2871 nt) in the MUC5AC
promoter and IL1b activates binding of CREB
to that site in NCI-H292 and differentiated HNE
cells (Song et al. 2003), as well as in A549 and
differentiated HBE cells (YA Chen, AM Watson,
LM Garvin, et al., unpubl.). In contrast, one
study shows that HBE1 cells exposed to IL1b
result in binding of the NFkB subunit p50
to a NFkB cis-site (23594/23582 nt) in the
MUC5AC promoter (Fujisawa et al. 2009).
Binding of CREB to the CRE cis-site is also ac-
tivated by the prostaglandins PGE2 (Gray et al.
2004) and PGF2a (Chung et al. 2009) in NCI-
H292 and differentiated HBE cells. ATP expo-
sure to NCI-H292 cells induces signal transduc-
tion pathways that activate CREB binding to the
CRE site and also activate E26 transformation-
specific (Ets)1 binding to a nearby c-Ets1 site in
the MUC5AC promoter (Song et al. 2008).
Posttranscriptional Regulation of
Secretory Mucin Genes
Some mediators (acrolein, TNFa, neutrophil
elastase) regulate secretory mucin genes post-
transcriptionally (for review, see Rose and Voy-
now 2006). IL8, which is present at high levels in
CF airways, does not transcriptionally regulate
secretory mucin gene expression but, rather, in-
creases MUC5AC and MUC5B mRNA abun-
dance in A549, H292, and differentiated HBE
cells posttranscriptionally. IL8 increases the
half-life of mucin transcripts and induces bind-
ing of RNA-binding proteins to specific sites
in the 30-untranslated sequence of MUC5AC
(Bautista et al. 2009).
Repression of MUC5AC Gene Expression
Pharmacological agents like glucocorticoids and
macrolides that are used to treat lung diseases
also reduce mucin gene expression. Studies to
investigate mechanisms, especially under con-
ditions in which lung epithelial cells are exposed
to inflammatory mediators, are underway in
several laboratories. The glucocorticoid dexa-
methasone (Dex) transcriptionally represses
MUC5AC gene expression following binding
of Dex-activated GR to two GRE cis-sites on
the MUC5AC promoter in A549 (Chen et al.
2006) and in differentiated HBE cells (Chen
et al. 2012) and is mediated by histone deacety-
lase 2 (Chen et al. 2012).
Themacrolideantibioticazithromycin(AZT),
which at low doses improves clinical outcome
in CF patients, alters the gene profile of differ-
entiated HBE cells by significantly increasing
the expression of lipid/cholesterol genes and
decreasing the expression of cell cycle/mito-
sis genes. Interestingly, AZT pre-treatment of
cells exposed to inflammatory stimuli does not
prevent up-regulation of most inflammatory
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mediators, but prevents up-regulation of the
MUC5AC gene (Ribeiro et al. 2009), suggesting
that AZT may directly impact expression of that
mucin gene. In H292 cells, AZT and clarithro-
mycin have inhibitory effects on MUC5AC
mRNA levels induced by HNP-1 or lipopolysac-
charide (LPS), whereas telithromycin, a semi-
synthetic erythromycin, has an inhibitory effect
on MUC5AC production induced by LPS, but
not by HNP-1. All three compounds have in-
hibitory effects on ERK1/2 phosphorylation in-
duced by LPS, but not by HNP-1, indicating
that these compounds interfere with different
intracellular signal transduction pathways (Ishi-
moto et al. 2009).
Summary: Mucin Gene Regulation
The MUC5AC gene is typically expressed in
goblet cells in the conducting airway epitheli-
um, which are well positioned to respond to
environmental and pathogenic airborne chal-
lenges. The MUC5B gene is typically expressed
in glandular mucosal cells in healthy lungs and
also in secretory cells in the conducting airway
epithelium in diseases conditions. Both mucin
genes are up-regulated by inflammatory medi-
ators that impact diverse pathways and activate
various transcription factors in lung epithelial
cells. Although inroads into understanding the
complexity of how MUC5AC gene expression is
up-regulated and repressed, information on
regulation of MUC5B gene expression is more
limited. Accumulating data show that regula-
tion of both MUC5AC and MUC5B genes is
modulated by diverse pathways in lung epithe-
lial cells and that mechanisms in lung cancer cell
lines, immortalized cells, and primary differen-
tiated HBE cells are often, but not always, sim-
ilar. Increased knowledge of the transcription
factors and functional cis-sites in the 50-flanking
region and of the RNA-binding proteins and
30-untranslated sites in polymeric MUC genes
that are responsive to inflammatory mediators
and to pharmacological agents will require ad-
ditional studies to address their therapeutic
impact. Further areas ripe for investigation in-
clude posttranscriptional and epigenetic regu-
lation of mucin gene expression, as well as phar-




Inflammation is commonly thought of as being
caused by infection and, as presented above,
clearly impacts mucus overproduction. Other
processes, for example, goblet cell and glandular
hyperplasia, contribute to mucus overproduc-
tion (Rose and Voynow 2006). However, there
are clearly non-infectious causes of mucus
overproduction, as exemplified by the selective
transgenic overexpression of bENaC in Clara
cells in murine lungs using the CC10 promoter
(Mall et al. 2004a; Zhou et al. 2011). Chronic
inhibition of Naþ in the mice by delivering ami-
loride in an aerosol blocks the mucus pheno-
type (Zhou et al. 2008), suggesting that it is not
the overexpression of ENaC, per se, that drives
the inflammation. Although there are few signs
of lung infection in bENaC Tg mice, some bac-
teria can be detected as expected because micro-
biome studies show a natural flora in the lungs.
However, raising the mice in a germ-free (gno-
tobiotic), LPS-free facility yields mice with the
same mucus plugging phenotype (Livraghi-Bu-
trico et al. 2012). Hence, the inflammation and
mucus metaplasia/overproduction appear to
be caused by hyperabsorption of airway surface
liquid and resulting concentration of the mucus
gel rather than being secondary to bacterial in-
fection. The implication of this observation is
that the epithelium initiates an inflammatory
attack against what it senses on the luminal sur-
face as an abnormal mucus gel.
Notably, this hypothesis offers an explana-
tion for the mucus meta/hyperplasia and plug-
ging observed in many organs of CF patients
that are not affected by bacterial infections
(Quinton 2010). The cause of mucus plugging
in many CF organs is uncertain, especially those
that do not express ENaC and therefore do not
experience the degree of dehydration that oc-
curs in the airways (Donaldson and Boucher
2007; Bridges 2012). A hypothesis gaining
widespread interest revolves around a deficiency
in HCO3
2 caused by functional impairment of
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mutated CFTR (Donaldson and Boucher 2007)
and a resulting, profound failure of mucins to
mature properly following their exocytic release,
resulting in the formation of a dense, sticky mu-
cus (Quinton 2010). This abnormal mucus is
speculated then to trigger an inflammatory re-
sponse in the epithelium, possibly similar to that




The emerging paradigm with regard to CF and
mucins, as presented above, is that CFTR is not
expressed in goblet or mucosal cells and thus
does not directly impact fundamental processes
in mucin production and secretion. Neverthe-
less, mucins are clearly overproduced in CF and
affect the morbidity and mortality of CF pa-
tients. Therefore, the current status of mucin
biosynthesis, glycosylation, and secretion, as
well as of mucus dynamics, and their contribu-
tion to CF diseases are reviewed below.
Mucin Biosynthesis and Assembly
Historically, mucin biosynthesis in intestinal
goblet cells played an important role in unrav-
eling the cell biology of protein synthesis and
secretion; for example, the Golgi apparatus was
originally identified as the site of protein glyco-
sylation (Peterson and LeBlong 1964) using 3H-
glucose labeling of what we now know to be
MUC2. Mucins are similar to other proteins
and glycoproteins in their synthesis, contrasting
mainly by virtue of their immense size and ex-
tensive glycosylation (for a recent review, see
Thornton et al. 2007). They are secreted or lo-
calized to plasma membranes, thus their prima-
ry functions are centered on the extracellular
environment, and their protein backbones are
synthesized by ribosomes associated with the
endoplasmic reticulum. The polymeric mucin
proteins are dimerized in the endoplasmic re-
ticulum lumen via their carboxy-terminal cys-
teine knot domains (Fig. 1A) (Dekker and
Strous 1990; Bell et al. 2001). A specific protein
disulfide isomerase, AGR2, has recently been
shown to be essential for intestinal mouse
Muc2 biosynthesis, because knockout of AGR2
leads to the loss of mucin secretion and colitis
(Park et al. 2009). After transit to the Golgi ap-
paratus, the mucin proteins (apomucins) are
glycosylated, multimerized in the case of the
polymeric species, and sorted at the trans-Golgi
network into the regulated (polymeric mucins,
MUC7) or constitutive (tethered mucins) limbs
of the secretory pathway (see Davis and Dickey
2008). Recent studies with MUC5AC have re-
vealed that GalNAc residues are transferred to
serine and threonine residues in the MUC5AC
apomucin in the Golgi and that stepwise syn-
thesis and elongation of the final O-glycan
structures are elaborated quickly in the HT-29
gastric cell line (Sheehan et al. 2004). Fully gly-
cosylated lung mucins are filamentous (Rose
et al. 1984), and mucin dimers of the polymeric
mucins are on the order of 1 mm in length, and
5 MDa in molecular mass (Thornton et al.
2007). The importance of carboxy-terminal
dimerization and amino-terminal multimeriza-
tion of polymeric mucins was recognized with
the sequencing of MUC2 and the identifica-
tion, respectively, of the cystine knot and D do-
mains, both having high homology to the re-
spective domains of von Willebrand factor
(vWF) (Gum et al. 1992; Desseyn et al. 2000).
Present efforts on the assembly of polymeric
mucins are using the recently revealed multi-
merization mechanism for vWF as a model
(Huang et al. 2008). Given the scale of complex-
ity and sizes of these massive molecules, the
recent estimate for the full biosynthesis of a mu-
cin polymer molecule in 2–4 h (Sheehan et al.
2004) is truly a remarkable feat of biology!
Mucin Secretion and Regulation
The sequence of signaling events regulating the
exocytosis of mucin granules in goblet cells is
complex and in a recent review (Davis and
Dickey 2008) has been shown to share similar-
ities with other secretory cells, for example,
neurons, neuroendocrine cells, and pancreatic
acinar cells (Burgoyne and Morgan 2003).
Briefly, mucin granules are released via Ca2þ-
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dependent exocytosis following interaction of
an agonist with the goblet cell, with the best
described secretagogues being ATP and UTP,
agonists of the P2Y2 receptor, coupled to
Gaq/11 and intracellular Ca2þ store mobiliza-
tion (Kreda et al. 2007; Davis and Dickey 2008).
However, other Ca2þ-dependent agonists like
serine proteases acting via protease-activated
receptors have been recently identified as im-
portant mucin secretagogues in airway epithelia
(Kreda et al. 2010). In the airways, cAMP-me-
diated agonists (e.g., isoproterenol) that acti-
vate CFTR do not stimulate mucin secretion
from goblet cells (Davis and Dickey 2008), re-
inforcing the concept that the activation or in-
hibition of CFTR has no effect on mucin secre-
tion (see Fig. 3) (Kreda et al. 2007), although
cAMP does mediate mucin secretion in intesti-
nal goblet cells (Bradbury 2000; Garcia et al.
2009). Interestingly, mucin secretagogues may
also up-regulate mucin gene expression in vitro.
For example, UTP, but not ATP, has been shown
to up-regulate expression of the MUC5AC and
MUC5B mucin genes in differentiated HBE
cells (Chen et al. 2001b), but similar results
have not been obtained in cancer cell lines.
ATP has been reported to up-regulate MUC5AC
gene expression in NCI-H292 cells in one study
(Song et al. 2008), but another study showed
that ATP does not increase MUC5AC protein
levels in H292 cells (Rada et al. 2011). In differ-
entiated HBE cells. neutrophil elastase func-
tions both as a mucin secretagogue (Park et al.
2005) and an up-regulator of MUC5AC gene
expression (Fischer and Voynow 2002; Voynow
et al. 2004).
Recently, activations of the small G-protein
RhoA and its downstream effector Rho kinase
(ROCK) have been identified as critical steps in
mucin granule exocytosis (Kreda et al. 2010).
The main downstream effector of ROCK in air-
way goblet cells appears to be myosin light chain
kinase (MLCK) (Seminario-Vidal et al. 2009;
Kreda et al. 2010), which is essential in acto-
myosin cytoskeleton remodeling during mucin
granule exocytosis (Davis and Dickey 2008;
Kreda et al. 2010). However, other ROCK tar-
gets involved in agonist-stimulated granule se-
cretion have been described; for example,
ROCK has been described to regulate MARCKS
by phosphorylation (Sasaki 2003). MARCKS is
also activated downstream from PKC and has
been reported to regulate mucin granule exocy-
tosis (Li et al. 2001; Singer et al. 2004).
The last steps of exocytosis are effected by
the proteins that tether and dock the granule at
the plasma membrane before exocytic fusion.
The proteins that regulate this process have
been well reviewed (Burgoyne and Morgan
2003; Davis and Dickey 2008). In regulated exo-
cytosis of mucin granules, this interaction re-
quires activation of Munc13 in a process termed
“priming,” by which Munc13 opens the confor-
mation of the soluble NSF attachment protein
(SNAP) receptors (SNAREs) to allow the as-
sembly of the “core complex” or “SNARE
core” (Davis and Dickey 2008). Genetic ablation
of the Munc13-2 isoform in mice produces a
defect in mucin secretion that is reflected, in
part, by an accumulation of mucin granules
within the goblet cells (Zhu et al. 2008). The
SNARE complex, required for rapid fusion of
the granule and cell membranes, is formed by
the interaction of one R-SNARE, or VAMP (ves-
icle-associated membrane protein), and two or
three Q-SNARES, whose identities in goblet
cells remain undefined (Burgoyne and Morgan
2003; Davis and Dickey 2008). Syntaxins 2, 3,
and 11 are candidate Q-SNARES for mucin
granule exocytosis, and we have shown that
syntaxin 3 is specifically localized apically in air-
way goblet cells (Kreda et al. 2007). Similarly,
SNAP23 or SNAP25 has been postulated as the
other Q-SNARE in the exocytotic core of mucin
granules (Davis and Dickey 2008; Evans and
Koo 2009), and deep-sequencing mRNA data
showed that SNAP23, but not SNAP25, is highly
expressed in airway epithelial cells (Jones et al.
2011). VAMP8 appears to be the R-SNARE in
the exocytotic core of goblet cells because it is
more than 10 times more highly expressed than
other VAMPs in airway epithelial cells, and spe-
cific reduction of VAMP8 expression drastically
decreases basal and agonist-mediated mucin
granule exocytosis in airway goblet cells (Jones
et al. 2011). Thus, a probable conformation of
the mucin granule SNARE complex has VAMP8
in the granule membrane and SNAP23 and
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syntaxin 3 in the plasma membrane of airway
goblet cells. The core complex activity is acutely
regulated in response to second messengers
Ca2þ and DAG, and the low-affinity, fast calci-
um-sensing synaptotagmin-2 is required for
this activity in airway goblet cells as it is in neu-
rons (Davis and Dickey 2008), because knock-
out of the isoform in mice produces a severe
defect in ATP-induced mucin secretion in the
airways (Tuvim et al. 2009).
Identification of other signaling compo-
nents of the mucin secretory pathway (Davis
and Dickey 2008) will be possible by genetic
and pharmacological manipulations and high-
throughput analysis of expression data, as well
as high-resolution video-microscopy tech-
niques. Importantly, some of these signaling
components might be good targets for thera-
peutic inhibition of mucin hypersecretion in
CF-affected organs, possibly as a prelude to in-
tervention with anti-inflammatory or other
therapeutic agents.
Mucin Glycosylation and CF
The O-glycans attached to serines and threo-
nines in MUC protein backbones account for
50%–90% of the molecular mass of mucins
(Fig. 1A,B). Historically, aberrant glycosylation
of mucins in CF patients figured large before the
cloning of CFTR in 1989, because there were
several reports of higher levels of acidic mucins,
along with increases in sulfation and either
increases or decreases in the fucosylation and
sialylation of mucins (Roussel et al. 1975; Chace
et al. 1983; Cheng et al. 1989; also, for review, see
Rose 1988; Rose and Voynow 2006). With the
identification of CFTR and the suggestion that
its effective absence from organelle and plasma
membranes in CF cells was responsible for alka-
lization and dysfunction along the secretory
pathway (Barasch et al. 1991; Barasch and al-
Awqati 1993), a possible mechanism was sug-
gested. After many years of controversy, which
led to increasingly sophisticated studies, the is-
sue appears to have been resolved with the
weight of the evidence indicating the physical
absence of CFTR in the Golgi apparatus (see
above), and no apparent role for CFTR in the
maintenance of Golgi pH (Seksek et al. 1996;
Gibson et al. 2000; Chandy et al. 2001; Haggie
and Verkman 2009) or in the glycosylation of
mucins and other glycoproteins (Jiang et al.
1997; Holmen et al. 2004; Leir et al. 2005). Bio-
chemical analyses of O-glycans indicate that
changes in glycosylation of CF mucins appear
to be a secondary effect of the disease that
is largely due to inflammation (Davril et al.
1999; Roussel and Lamblin 2003; Schulz et al.
2007). Consistent with this notion, recent ob-
servations indicate that cytokines and other
inflammatory mediators not only induce in-
creases in mucin gene expression (as reviewed
above) but also increase the expression of gly-
cosyltransferases and sulfotransferases within
the bronchial mucosa (Delmotte et al. 2002;
Groux-Degroote et al. 2008). Possibly because
of the large number and diversity of glycosyl-
transferases (Brockhausen et al. 2009), their
roles in mucin synthesis and mucus biology
are vastly underappreciated. The number of in-
vestigators in this field is small, but they are
persistent, and a basic understanding of glyco-
syltransferase cell biology and physiology as it
relates to mucin O-glycosylation is gradually
emerging (Ten Hagen et al. 2003; Cheng and
Radhakrishnan 2011; Gerken et al. 2011). This
information will impact our understanding of
the molecular roles of O-glycans in specific mu-
cins and their functions in protecting the epi-
thelium against pathogens in health and disease,
including CF.
Dynamics of Mucus Formation and Function
The world of mucus is dynamic. These dynam-
ics are perhaps most obvious in the airways,
where beating cilia drive a sheet of mucus ceph-
alad, continuously, as reported by Florey et al.
(1932). Recent, closer observation by modern
video-microscopy has revealed that polymeric
mucins, MUC5B in particular, form strands
and clumps that bind transiently to the tips of
beating cilia and appear to be transported by
being passed along from one ciliated cell to
the next (Sears et al. 2011). These observations
suggest a much closer and dynamic interaction
between mucin molecules and ciliary surfaces
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than previously suspected, and imply transient
molecular binding interactions forming be-
tween MUC5B and ciliary surfaces.
More subtly, mucus on mucosal surfaces is
constantly being formed and degraded. Clara
cells in the mouse airways do not react with
periodic acid Schiff (PAS) stain, the archetypal
mucin stain (Spicer et al. 1971). However, in the
Munc13-2-null mouse, which has a defect in
basal mucin secretion, the cells are PASþ, indi-
cating an apparent accumulation that occurs as
a result of hindered release of mucins (Zhu et al.
2008). Similarly, mucins are released continu-
ously in the intestinal tract, forming the adher-
ent mucus layer in the colon and stomach, then
becoming part of the “floppy” layer as cross-
links responsible for the mesh-like arrangement
in adherent layers are cleaved (Johansson et al.
2011; Ambort et al. 2012).
Even more subtly, mucus dynamics ex-
tends to the birth of mucins following their
exocytic release from goblet and mucous cells.
It has long been appreciated that mucins expand
enormously as they hydrate following exocytic
release from goblet cells, a process that was
thought to be due to ionic repulsion of the fixed
negative charges on mucin O-glycans, because
Ca2þ packaged with the mucins was exchanged
for Naþ on the luminal surface (Verdugo 1991,
2012) A recent analysis of salivary MUC5B
mucin implies an even more ordered packing
of mucins in secretory granules than previous-
ly imagined. In these studies (Kesimer et al.
2009a), salivary MUC5B was subjected to den-
sity gradient centrifugation, which revealed
three morphotypes of mucin by electron mi-
croscopy. One, a “compact form” that com-
prised ,10% of the total MUC5B in the sam-
ple, migrated to the bottom of the gradient. The
polymer molecules had roughly circular profiles
and cross-linked in such a way that the amino-
and carboxy-terminal domains, arranged as no-
des ~10 nm in diameter, were in the central part
of the complex, with the glycosylated domains
of the mucin arrayed in the outer parts. Present
in the middle of the gradient was a “moderately
compact form,” one in which the mucin ap-
peared to be in the process of expanding from
the compact form. And, at the top of the gradi-
ent, representing the bulk of the total MUC5B,
was the “linearized form,” in which the mucins
assumed open, linear, non-cross-linked confir-
mations. The hypothesis offered, presently un-
der evaluation, is that the “compact form” rep-
resents a mucin molecule right after exocytic
release into the luminal environment, and that
it undergoes a maturation process, which may
involve enzymatic cleavage, following which it
assumes the “linearized form”; following this it
is fully rendered into the mucus gel.
CONCLUSIONS AND EMERGING
DIRECTIONS
The mechanism of mucin secretion in CF mu-
cosal cells is normal and does not appear to be
linked in any direct way to CFTR. Similarly, the
mucus hyperproduction that typifies CF does
not appear to be a direct cause of a defective
CFTR, a major reason being the lack of CFTR
expression in most mucin-secreting (goblet,
mucous) cells. The overwhelming weight of
the evidence reviewed above favors an indirect
connection between CFTR expression and mu-
cin overproduction in CF. The downstream
consequences of mutant CFTR, for example,
the lack of functional CFTR at the plasma mem-
brane, clearly affect mucin overproduction in
individuals with CF in ways that are not yet
well understood. This is most apparent in CF
lungs, where chronic inflammation and infec-
tion sustain conditions wherein mucin genes
are up-regulated, resulting in increased pro-
duction and secretion of polymeric mucins.
Although recent studies from several laborato-
ries have reinforced the concept that diverse
stimuli modulate expression of the MUC5AC
and MUC5B mucin genes in lung epithelial cells,
regulation of these genes is complex. Additional
studies are required for a full understanding
of how these genes are modulated in CF and
non-CF cells before therapeutic interventions
can be maximized. In addition to inflammation
that arises from infection, other pathways may
stem from luminal environments gone awry.
ThebENaC-overexpressing mouse mucus plug-
ging phenotype is proving to be an archetypal
example of this kind of inflammation, with a
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dehydrated airway surface/concentrated mucus
gel apparently providing the inflammatory
stimulus. We speculate that the luminal HCO3
2
deficiency presently being described for CF ep-
ithelia may also provide such a stimulus, by
causing a mal-maturation of mucins as they
are released onto luminal surfaces. The molecu-
lar mechanisms triggered by these stimuli have
not been identified, but they are presently under
study in multiple laboratories. Additionally, in-
nate immune defense proteins secreted by lung
cells that express CFTR may be altered in their
levels or properties in CF patients as a direct
consequence of CFTR, thereby contributing to
the pathogenesis of CF lung diseases.
We continue to be amazed at the complex,
pervasive pathways of dysfunction manifested
in numerous cells and organs that result from
gene defects in a single gene, CFTR, that under-
lies CF disease, especially mucosal epithelia.
Thirty years ago, CF was thought to be a disease
of mucus. Twenty years ago, the identification
of CFTR as a Cl2 channel caused the field to
shift its attention dramatically away from mucus
and mucins. Ten years ago, we began to appre-
ciate that tertiary or higher-order effects of the
defect in CFTR were driving mucus dysfunction
and hyperproduction in CF. Finally, today, we
may be approaching a full understanding of the
train of molecular events that lead from muta-
tions in CFTR to mucus overproduction, pos-
sibly via defects induced in the postsecretory
maturation of mucins. In light of the numerous
systems, organs, and tissues that are affected, CF
is a systems biology disease, although it is the
lungs that account for morbidity and mortality.
Given the diversity of CFTR mutations, the
challenge of circumventing airway mucus ob-
struction may be amenable in the future to a
personalized-medicine approach to therapy.
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